EA201201660A1 - Очень высокая эффективность антител к cd37 в образцах крови страдающих cll пациентов - Google Patents

Очень высокая эффективность антител к cd37 в образцах крови страдающих cll пациентов

Info

Publication number
EA201201660A1
EA201201660A1 EA201201660A EA201201660A EA201201660A1 EA 201201660 A1 EA201201660 A1 EA 201201660A1 EA 201201660 A EA201201660 A EA 201201660A EA 201201660 A EA201201660 A EA 201201660A EA 201201660 A1 EA201201660 A1 EA 201201660A1
Authority
EA
Eurasian Patent Office
Prior art keywords
patients
antibodies
cll
treatment
blood samples
Prior art date
Application number
EA201201660A
Other languages
English (en)
Other versions
EA025365B1 (ru
Inventor
Штефан Штильгенбауэр
Торстен Ценц
Карл-Хайнц Хайдер
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44546328&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201201660(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201201660A1 publication Critical patent/EA201201660A1/ru
Publication of EA025365B1 publication Critical patent/EA025365B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

В заявке описаны антитела к CD37, прежде всего А2 и В2, предназначенные для лечения страдающих CLL пациентов, прежде всего пациентов, принадлежащих к группе "высокого риска" или "ультравысокого риска". Указанные пациенты представляют собой либо пациентов, невосприимчивых к лечению флударабином, либо пациентов, которые несут генетический маркер, свидетельствующий о плохом прогнозе или повышенном риске неблагоприятного исхода лечения, например пациентов с дисфункцией ТР53 или делецией хромосомы 17р13, либо пациентов с неблагоприятным исходом предшествующего лечения антителами к CD20. Способность А2 и В2 вызывать истощение CLL-клеток является высокой в образцах крови пациентов, взятых у пациентов из группы нормального риска и повышенного риска (пациенты "высокого риска"), и выражено превышает активность ритуксимаба и алемтузумаба.
EA201201660A 2010-07-16 2011-07-15 Применение антитела к cd37 для лечения пациента из группы высокого риска, страдающего хроническим лимфолейкозом (cll), способ истощения экспрессирующих cd37 в-клеток в популяции клеток с дефицитом тр53 EA025365B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10169795 2010-07-16
EP10175586 2010-09-07
PCT/EP2011/062133 WO2012007576A1 (en) 2010-07-16 2011-07-15 Superior efficacy of cd37 antibodies in cll blood samples

Publications (2)

Publication Number Publication Date
EA201201660A1 true EA201201660A1 (ru) 2013-07-30
EA025365B1 EA025365B1 (ru) 2016-12-30

Family

ID=44546328

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201660A EA025365B1 (ru) 2010-07-16 2011-07-15 Применение антитела к cd37 для лечения пациента из группы высокого риска, страдающего хроническим лимфолейкозом (cll), способ истощения экспрессирующих cd37 в-клеток в популяции клеток с дефицитом тр53

Country Status (14)

Country Link
US (3) US20120189618A1 (ru)
EP (2) EP3252077A1 (ru)
JP (2) JP2013538790A (ru)
KR (1) KR20130100918A (ru)
CN (2) CN103003309A (ru)
AU (1) AU2011278227B2 (ru)
BR (1) BR112013001012A2 (ru)
CA (1) CA2799036A1 (ru)
CL (1) CL2013000101A1 (ru)
EA (1) EA025365B1 (ru)
IL (1) IL222775A (ru)
MX (1) MX341463B (ru)
NZ (2) NZ703225A (ru)
WO (1) WO2012007576A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090499A1 (es) 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
WO2013160396A1 (en) * 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
EP2849784A1 (en) * 2012-05-16 2015-03-25 Boehringer Ingelheim International GmbH Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
CN114149511A (zh) * 2015-04-13 2022-03-08 辉瑞公司 靶向b细胞成熟抗原的嵌合抗原受体
US11578115B2 (en) 2017-01-10 2023-02-14 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
EP3595721A4 (en) * 2017-03-16 2021-01-06 The General Hospital Corporation CHEMERICAL ANTIGEN RECEPTORS TARGETING CD37
KR20200074915A (ko) 2017-03-31 2020-06-25 젠맵 홀딩 비.브이. 이중특이적 항-cd37 항체, 모노클로날 항-cd37 항체 및 그의 사용 방법
JP7513530B2 (ja) 2018-06-22 2024-07-09 ジェンマブ ホールディング ビー．ブイ． 抗ｃｄ３７抗体および抗ｃｄ２０抗体、組成物、ならびにそれらの使用方法
MA53812A (fr) 2018-10-04 2021-08-11 Genmab Holding B V Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
WO2023057583A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
HUE026303T2 (hu) * 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
BRPI0814060A2 (pt) * 2007-07-06 2015-01-06 Trubion Pharmaceuticals Inc Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal
PE20090499A1 (es) * 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
DK2132228T3 (da) * 2008-04-11 2011-10-10 Emergent Product Dev Seattle CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf
CN102271708A (zh) * 2008-11-13 2011-12-07 新兴产品开发西雅图有限公司 Cd37免疫治疗联合疗法及其用途

Also Published As

Publication number Publication date
EP3252077A1 (en) 2017-12-06
US20120189618A1 (en) 2012-07-26
AU2011278227A1 (en) 2012-11-15
MX341463B (es) 2016-08-22
JP2017019800A (ja) 2017-01-26
EP2593479A1 (en) 2013-05-22
AU2011278227B2 (en) 2017-03-02
CN103003309A (zh) 2013-03-27
CA2799036A1 (en) 2012-01-19
BR112013001012A2 (pt) 2016-05-24
KR20130100918A (ko) 2013-09-12
WO2012007576A1 (en) 2012-01-19
NZ603161A (en) 2015-02-27
IL222775A0 (en) 2012-12-31
JP2013538790A (ja) 2013-10-17
NZ703225A (en) 2016-11-25
US20150266967A1 (en) 2015-09-24
EA025365B1 (ru) 2016-12-30
CL2013000101A1 (es) 2013-12-27
MX2012013613A (es) 2012-12-17
CN105749276A (zh) 2016-07-13
US20130236454A1 (en) 2013-09-12
IL222775A (en) 2017-10-31

Similar Documents

Publication Publication Date Title
EA201201660A1 (ru) Очень высокая эффективность антител к cd37 в образцах крови страдающих cll пациентов
Kurth et al. Cancer stem cell related markers of radioresistance in head and neck squamous cell carcinoma
Bosiljcic et al. Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs
Yung et al. GRO-α and IL-8 enhance ovarian cancer metastatic potential via the CXCR2-mediated TAK1/NFκB signaling cascade
Fleming et al. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study
Singh et al. Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis
Hao et al. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression
Liu et al. Elevated miR-155 expression induces immunosuppression via CD39+ regulatory T-cells in sepsis patient
Galore-Haskel et al. A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme
Sareen et al. The role of liquid biopsies in detecting molecular tumor biomarkers in brain cancer patients
MX2018011480A (es) Metodos de intervencion temprana para prevenir o aminorar toxicidad.
EA036698B9 (ru) Моноклональное антитело против lif человека и его применение для лечения рака с высоким уровнем lif
Chen et al. Esophageal cancer stem cells express PLGF to increase cancer invasion through MMP9 activation
CN107106876A (zh) 用于治疗免疫失调的多次‑可变il‑2剂量方案
Tao et al. Decrease of let-7f in low-dose metronomic Paclitaxel chemotherapy contributed to upregulation of thrombospondin-1 in breast cancer
Barnes et al. Economic comparison of an empirical versus diagnostic-driven strategy for treating invasive fungal disease in immunocompromised patients
Li et al. AMD3100 inhibits brain-specific metastasis in lung cancer via suppressing the SDF-1/CXCR4 axis and protecting blood-brain barrier
Nakasone et al. Therapeutic benefits targeting B-cells in chronic graft-versus-host disease
Liang et al. Paeoniflorin ameliorates murine lupus nephritis by increasing CD4+ Foxp3+ Treg cells via enhancing mTNFα-TNFR2 pathway
He et al. Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti–PD-1 in Metastatic Non–Small Cell Lung Cancer
Hussain et al. HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy
Asero Oral cyclophosphamide in a case of cyclosporin and steroid‐resistant chronic urticaria showing autoreactivity on autologous serum skin testing
US20190060361A1 (en) Methods and compositions relating to regulatory t cells
CN109512833B (zh) E2f6抑制剂的功能与用途
Shao et al. Combination of monoclonal antibodies with DST inhibits accelerated rejection mediated by memory T cells to induce long-lived heart allograft acceptance in mice

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU